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Abstract
Inflammatory bowel diseases, Crohn's disease and ulcerative colitis, are associated with a variety of
extraintestinal manifestations. The most common extraintestinal manifestation, articular involve-
ment, occurs in 16% to 33% of inflammatory bowel disease patients. These arthropathiesmay increase
morbidity, resulting in a worse quality of life compared with inflammatory bowel disease patients
without arthropathies. Thus, arthropathies in inflammatory bowel diseases represent a major
medical problem in these patients. Arthritis associated with inflammatory bowel diseases is one of
the diseases captured under the umbrella of spondyloarthritis. Spondyloarthritis is a group of
inflammatory diseases with overlapping features and is linked to Human Leukocyte Antigen-B27.
Arthropathy in inflammatory bowel diseases is clinically divided into peripheral and axial
involvement. Peripheral arthritis often flares with relapses of bowel disease resulting in a different
treatment approach than axial arthritis in which the course is independent of inflammatory bowel
disease activity. Definitions, prevalence, pathophysiology and treatment of the arthropathies
commonly seen in inflammatory bowel diseases such as peripheral arthritis, dactylitis, enthesitis,
arthralgia, sacroiliitis, inflammatory back pain and ankylosing spondylitis are summarized.
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Inflammatory bowel diseases (IBD), with its major forms
Crohn's disease (CD) and ulcerative colitis (UC), are chronic
diseases with a relapsing and remitting clinical course arising
from an interaction between genetic, immune and environ-
mental factors. The precise etiology is still unknown and
therefore a causal treatment is not yet available.
Apart from intestinal symptoms, IBD is associated with a
variety of extraintestinal manifestations (EIMs), with a
reported prevalence varying from 6 to 36%.1–5 These EIMs are
occasionally the presenting symptom. Themost common EIM in
CD and UC is articular involvement but, cutaneous, ocular,
hepatobiliairy and hematologicmanifestationsmay also occur.
The prevalence rates of arthropathy in IBD range between 16%
to 33% in both retrospective and prospective studies.2,4–9
Arthropathy in IBD patients is clinically divided into
peripheral and axial involvement. Peripheral arthritis (asym-
metrical, predominantly in the lower extremities) and/or
inflammatory spinal pain in IBD patients, with consistent
absence of the rheumatoid factor, is classified as one of the
spondyloarthritis (SpA) according to the most well-known
classification criteria the European Spondyloarthropathy
Study Group (ESSG).10 SpA is a group of inflammatory
diseases with overlapping features (e.g. psoriasis, uveitis
and IBD) and is linked to Human Leukocyte Antigen (HLA)-
B27. Other diseases included in the SpA group are ankylosing
spondylitis (AS), undifferentiated SpA, arthritis associated
with acute anterior uveitis, psoriatic arthritis, reactive
arthritis and idiopathic arthritis.The definitions for peripheral and axial arthropathies
commonly used will be summarized. The peripheral arthrop-
athies in IBD that will be discussed here includes peripheral
arthritis, enthesitis, dactylitis and arthralgia, and the axial
arthropathies associated with IBD includes isolated sacroilii-
tis, inflammatory back pain (IBP) and AS (Table 1).2. Definitions and clinical manifestations
2.1. Peripheral arthropathies
2.1.1. Peripheral arthritis
In 1998, the Oxford research group8 suggested that periph-
eral arthritis (without axial involvement) could be divided
into two groups: an oligoarticular large joint arthritis and a
bilateral symmetrical polyarthritis based on the different
distribution and natural history. Ever since, this division is
commonly used in gastroenterology research studies on
arthropathy in IBD patients, but remained rather unknown
in rheumatology literature. Orchard et al.8 defined type 1
(pauci/oligoarticular) peripheral arthritis as joint pain with
the evidence of swelling or effusion affecting fewer than 5
joints and mainly affecting the large weight bearing joints of
the lower limbs. These joint symptoms are usually acute and
self-limiting, resolve in less than 10 weeks, leave no
permanent joint damage and mostly occur during exacerba-
tions of IBD activity. Type 2 (polyarticular) peripheral
arthritis affects more than five joints, with a symmetrical
distribution and affects predominantly the small joints of the
Table 1 Definitions and prevalence of the arthropathies in
IBD.
Definitions Prevalence
Peripheral arthropathies
Peripheral
arthritis
Joint swelling and joint pain 7–16%
Type 1
peripheral
arthritis
b5 joints 4–8%
Mainly large weight bearing
joints of the lower limbs
Acute, self-limiting attacks
(b10 weeks)
Association with bowel activity8
Type 2
peripheral
arthritis
≥5 joints 1–3%
Mainly small joints of the upper
limbs
Symmetrical distribution
Duration usually months to years
No association with bowel
activity8
Enthesitis Pain and swelling at the site
where a tendon inserts the bone
5–10%
Dactylitis “Sausage-like digit” 2–4%
Entire digit is painful and swollen
Arthralgia Joint pain (without swelling) 8–30%
Axial arthropathies
Isolated
sacroiliitis
Diagnosis based on imaging
techniques showing sclerosis,
erosions and/or ankylosis of the
sacroiliac joint
2–32%
Inflammatory
back pain
The Calin criteria are fulfilled if
at least four out of the five
characteristics are present:
5–30%
Age of onset b40 years
Insidious in onset
Duration≥3 months
Association with morning
stiffness
Improvement after exercise23
Ankylosing
spondylitis
Diagnosis based on a
combination of inflammatory
back pain symptoms, limitation
in spinal mobility and imaging
techniques showing bilateral
sacroiliitis grade≥2 or unilateral
sacroiliitis grade 3–425
1–10%
259The joint–gut axis in inflammatory bowel diseasesupper limbs. Symptoms persist in episodes for months to
years and follow a course independent of the activity of IBD.
Peripheral arthritis in IBD patients is mostly asymmetric and
oligoarticular6,7,11–13 and is predominantly seen in
CD.2,3,5,6,9,13 One study reported an increased prevalence
in patients with CD localized in the colon.14 The onset may
precede the onset of bowel symptoms although it usually
coincides with or presents after the onset of IBD.8,15 The
prevalence in IBD patients ranges from 7 to 16%,3,5,8,12,13,16
5–14% in UC3,5,8,12,13 and 10–20% in CD3,5,8,12,13 in several
studies, depending on study design, the population assessed,
and the duration of the intestinal disease. Studies using thetype 1 and 2 subdivision of Orchard et al.8 show a prevalence
of 4–8% of type 1 arthritis and 1–3% of type 2 arthritis in IBD
patients.3,8,9
IBD associated with peripheral arthritis is diagnosed
clinically based on exclusion of other specific forms of
arthritis. Clinical examination includes palpation of the
joints that may reveal pain and swelling in one or more of
the joints. Aspiration of articular fluids is unnecessary unless
an alternative diagnosis, such as septic arthritis or gout is
suspected.8,17,18
2.1.2. Enthesitis and dactylitis
Enthesitis and dactylitis in IBD patients have been studied
less well than peripheral arthritis. Peripheral enthesitis is an
inflammation of the site where a tendon inserts the bone, for
example, the insertion of the Achilles tendon into the
calcaneus. Patients may suffer from severe pain, tenderness
and swelling. In small studies, the prevalence of enthesitis in
IBD ranges from 5–10%.6,9,11,16
Peripheral dactylitis, also known as sausage-like toe or
sausage-like finger, is a characteristic and highly specific
feature of SpA. Clinical examination shows a painful and
diffuse swelling of the entire digit due to flexor tenosynovitis
and marked adjacent soft tissue swelling in which small joint
synovitis may occur. Salvarani et al.9 and Palm et al.16
respectively reported a prevalence of 2% and 4% of dactylitis in
IBD patients.
2.1.3. Arthralgia
Arthralgia is (non-inflammatory) joint pain without objective
evidence of swelling or effusion and has been excluded inmost
studies on arthropathy in IBD patients. Two large studies
reported a prevalence of arthralgia in IBD patients of 8% and
16% and one smaller study showed a prevalence of 30%.8,11,19
Palm et al.19 investigated the impact of non-inflammatory
joint pain in IBD patients on health related quality of life
(HRQOL assessed by SF-36 and IBDQ). They found arthralgia in
85 (16%) of the 521 patients and these patients had a
significantly lower HRQOL score indicating a worse health
related quality of life compared with IBD patients without
arthralgia, thus representing a major medical problem in IBD
patients.
2.2. Axial arthropathies
Axial arthropathy associated with IBD includes isolated
sacroiliitis, IBP and AS. The onset of axial involvement
frequently precedes that of IBD, the course is independent of
the IBD course and bowel surgery does not alter the course of
associated sacroiliitis or AS.20
2.2.1. Isolated sacroiliitis
Isolated sacroiliitis is an inflammation of the sacroiliac (SI)
joints, consisting of uni- or bilaterally inflammation, which is
mostly asymptomatic. Symptomatic patientsmay presentwith
pain in the pelvis and/or decreased spinal mobility. Sacroiliitis
is diagnosed by imaging methods such as conventional radio-
graphs and CT showing sclerosis, erosions and/or ankylosis, or
by MRI showing acute inflammation with or without structural
changes. The prevalence of sacroiliitis in IBDpatients in studies
varies widely from 2 to 32%.5,11,12,16,21,22 Dekker et al.12 found
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and part of bowel involvement, or extent of bowel involve-
ment in a group of 109 IBD patients with sacroiliitis. Further-
more, there was no correlation between the radiographic
grading of sacroiliitis and the duration of bowel disease. In
contrast, de Vlam et al.11 found sacroiliitis to be more
prevalent in patients with disease duration over 10 years
compared to those with a duration of 5 or less years.
2.2.2. Inflammatory back pain
IBP, a consequence of inflammation of the SI joints that may
spread to the spine in the majority of patients, is the major
clinical symptom of AS and several clinical classification
criteria exist to differentiate between inflammatory and
mechanical back pain.10,23,24 IBP is characterised by an
insidious onset, improves after exercise but not with rest, and
is associated with morning stiffness. It may also present as
pain during the second half of the night and/or alternating
buttock pain. The most frequently used set of criteria for IBP
is the Calin criteria (Table 1).23 In studies that use these
criteria the prevalence of IBP in IBD patients ranges from
5%–30%.6,8–11,16
2.2.3. Ankylosing spondylitis
AS, the most typical representation of SpA, is a chronic
inflammatory disease of the axial skeleton (spondylitis,
spondylodiscitis, spondyloarthritis and/or sacroiliitis), in
which other locations in the body can also be affected e.g.
peripheral arthritis and enthesitis. AS most often affects
white males with onset between 15 and 40 years of age and
causes symptoms of inflammatory low back pain with
eventually loss of the lumbar lordosis and a limitation in
spinal mobility due to spinal deformities. AS is diagnosed
clinically, using IBP criteria, and supported by radiological
sacroiliitis. The last modification of the New York criteria
(Table 2) are the most widely used criteria set for
classification of AS in IBD patients.23,25–27 Prevalence in IBD
patients varies from 1 to 10%.8,11,12,16,21 Palm et al.16 found
no correlation between localization or extent of the
intestinal inflammation and presence of AS.
2.2.4. New classification sets
The Assessment of SpondyloArthritis international Society
(ASAS), a group of rheumatologists who are consideredTable 2 Modified New York criteria for ankylosing
spondylitis.25
Clinical criteria
Low back pain and stiffness for more than 3 months, which
improve with exercise, not relieved by rest.
Limitation of motion of the lumbar spine in both the sagittal
and frontal planes.
Restriction of chest expansion relative to normal values
corrected for age and sex.
Radiological criterion
Bilateral sacroiliitis grade ≥2 or unilateral sacroiliitis
grade 3–4.
Definite ankylosing spondylitis if the radiological criterion is
associated with at least one clinical criterion.experts in SpA, defined new criteria for IBP in patients with
chronic back pain. These criteria developed and validated by
ASAS had a sensitivity of 80% and specificity of 72% in a
validation cohort which performed better as the widely used
Calin criteria. The ASAS IBP criteria are fulfilled if at least
four out of the following five parameters are present: 1) age
at onset b40 years, 2) insidious onset, 3) improvement with
exercise, 4) no improvement with rest and 5) pain at night
(with improvement upon getting up).28
SpA patients can be subdivided into peripheral SpA with
predominantly peripheral joint involvement and axial SpA
with predominantly axial involvement. In June 2009, the
ASAS group published new classification criteria for axial SpA
including radiographs as well as MRI. These criteria include
patients with chronic back pain and radiographic sacroiliitis
(that will be classified as AS) and also patients with chronic
back pain who have not yet developed radiographic sacroi-
liitis (early stage of AS).29,30 In addition, patients without
sacroiliitis on imaging can be classified as having axial SpA if
they are HLA-B27 positive and have two additional clinical
features. IBD is one of the possible clinical features. Patients
presenting with arthritis, enthesitis and dactylitis in combi-
nation with 1–2 other clinical features (again IBD is one of
these features) are classified as having peripheral SpA
[unpublished data/to be published: Rudwaleit et al. New
ASAS classification criteria for peripheral spondyloarthritis
(abstract EULAR 2009) Ann Rheum Dis 2009;68(Suppl3):127].
In conclusion, arthropathy in IBD is divided into peripheral
and axial involvement and may be classified as SpA. Most
studies focus on peripheral arthritis, isolated sacroiliitis, IBP
and AS in IBD patients. The type 1 and 2 subdivision in
peripheral arthritis is rather unknown in rheumatology
literature and therefore, possibly of limited value for clinical
diagnosis of peripheral arthritis in IBD patients.
3. Laboratory
There is no reliable laboratory test that can be used as a
diagnostic tool in the management or diagnosis of arthrop-
athy in IBD.
3.1. HLA-B27
A strong association exists between HLA-B27 and AS patients
in whommore than 90% of patients are HLA-B27 positive. The
frequency of HLA-B27 in IBD patients was found to be similar
to the general population. On the other hand, 25–78% of IBD
patients with AS are HLA-B27 positive.16,31–33 In contrast,
isolated sacroiliitis in CD patients is unrelated to HLA-
B27.22,31,33
3.2. Anti-CCP
Antibodies recognizing cyclic citrullinated peptides (anti-
CCP) are highly specific for rheumatoid arthritis. Koutroubi-
kas et al.34 investigated the prevalence of anti-CCP in a
group of 222 IBD patients (history of arthritic involvement in
16.7% IBD patients, 70 RA patients and 103 healthy controls).
They found no differences in the prevalence of anti-CCP
between IBD patients and healthy controls and between IBD
261The joint–gut axis in inflammatory bowel diseasespatients with or without arthritic manifestations, suggesting
that the development of arthropathy in IBD patients is not
correlated to the presence of anti-CCP.
Statements
- No reliable laboratory test for the management or
diagnosis of arthropathies in IBD patients exists.
- AS but not sacroiliitis in IBD patients is associated with
HLA-B27.
- Arthropathy associated with IBD is unrelated to anti-
CCP.4. Imaging
4.1. Peripheral arthropathies
Peripheral arthritis in IBD patients is usually nondeforming
and nonerosive.9 Therefore, radiographs of peripheral joints
do not show erosions. Mielants et al.35 found destructive
lesions of the small joints, mainly metacarpophalangeal and
metatarsal joints, more frequently in SpA patients presenting
subclinical inflammatory gut lesions, predominantly of the
chronic type, than in patients without gut inflammation.35,36
Ultrasonography and MRI studies on dactylitis showed
fluid collection in the flexor synovial sheaths (flexor
tenosynovitis) and soft tissue oedema with a variable degree
of small joint synovitis.37
4.2. Axial arthropathies
Diagnosis of sacroiliitis (often asymptomatic) is based on
imaging techniques, in which plain radiography of the AP
pelvis remains the most widely accepted and available initial
screeningmethod. Advanced inflammation results in sclerosis
and cartilage destruction, eventually leading to syndesmo-
phytes and partial/total ankylosis of the SI joints. There is a
prolonged interval between the onset of inflammation of the
SI joints and/or IBP symptoms and the appearance of
objective radiographic findings of sacroiliitis. This prolonged
interval is due to limitations of the diagnostic capacity of
radiographs which is partly explained by the 2-dimensional
imaging of the anatomically complex SI joints.38,39 Several
studies reported a considerable intra- and interobserver
variability in diagnosing radiographic sacroiliitis, with most
variability occurring in stages 1 (suspicious changes) and 2
(minimal, abnormal changes with erosions or sclero-
sis).21,38,39 As a result, a delay of 5–10 years may occur in
the diagnosis of AS according to the modified New York
criteria in which radiographic sacroiliitis of at least grade 2
bilaterally or grade 3 unilaterally is needed (Table 2).40 The
prevalence rate of radiographic sacroiliitis is probably
underestimated as reflected by higher prevalence rates
found in studies using more sensitive imaging techniques
than plain radiographs.21 In 2008, Song et al.41 performed a
systematic literature research to assess the diagnostic value
of scintigraphy in detecting sacroiliitis in patients with SpA.
They reported a sensitivity of a positive scintigraphy of the SIjoints of 52% and a specificity of 78% and concluded that there
are too many non-specific factors such as movement of the
patient during the examination, age, and technical problems
that may influence the accumulation of radiopharmaceuti-
cals at normal bony sites to use a positive scintigraphy alone
for the diagnosis of sacroiliitis. CT and MRI have the
advantage of improved view of the complex anatomy of the
SI joints in comparison to radiography and scintigraphy.42 CT
reveals early bone changes such as erosions and sclerosis, but
is unable to differentiate between active and inactive
sacroiliitis.38 MRI may show abnormalities of bone, cartilage
and soft tissues and detect active sacroiliitis, especially in the
early phase of disease when no chronic changes are
detectable and therefore, has been of much additional
diagnostic benefit in early disease.27,42–48 In may 2009, a
group of rheumatologists and radiologists (ASAS/OMERACT
MRI working group) with experience in SpA and MRI described
MRI findings of sacroiliitis and also proposed a definition for
active sacroiliitis. They found that active inflammation of the
SI joints in SpA patients detected by MRI includes bone
marrow edema / osteitis, synovitis, enthesitis and capsulitis.
The ASAS/OMERACT MRI working group defined active
sacroiliitis on MRI (positive MRI) when bone marrow edema
or osteitis is present.49
Radiographic changes of chronic inflammatory and de-
structive spinal involvement in AS are sclerosis and syndes-
mophytes, but also vertebral bridging and fusion producing
the classical “bamboo spine” may be seen.27 MRI visualizes
both acute and chronic inflammation of the spine in SpA
patients.27,49–51
Thus, plain X-rays do not detect acute inflammation but
rather chronic changes as a consequence of chronic
inflammation of the SI joints as well as the spine. In contrast,
MRI shows active sacroiliitis and inflammation of the spine
and recently, a definition for active inflammation of the SI
joints on MRI, a positive MRI, has been proposed.
Statements
- Imaging of the joints of IBD patients with peripheral
joint symptoms are not required as a diagnostic tool
and are usually nondeforming and nonerosive.
- Plain radiographs detect chronic but do not detect
acute inflammation of the SI joints and the spine.
- A positive scintigraphy alone for diagnosing sacroiliitis
should not be used due too many non-specific factors.
- MRI visualizes both acute and chronic inflammation of
the SI joints and the spine resulting in early detection
of sacroiliitis and AS.
- Imaging (radiographs and/or MRI) of the SI joints and
spine is necessary in all IBD patients with high
suspicion of sacroiliitis, IBP or AS.5. Pathophysiology
The close relationship between joint and gut inflammation
has been confirmed by several studies. The prevalence of
articular involvement in IBD patients ranges from 16–33%. On
the other hand, involvement of the gastrointestinal tract as
262 L.K.P.M. Brakenhoff et al.feature of SpA was found in about 70% of patients and in the
long term, 7% to 12% of patients with SpA will develop overt
IBD, suggesting a shared aetiology.52–55
5.1. Lymphocyte recirculation and homing to gut
Naive lymphocytes recirculate between the blood and lymphoid
tissues in search of their cognate antigens that are transported
to the immune system via the gut epithelium and translocate
through specific epithelial cells of the intestine, theMcells, into
underlying Peyer's patches (secondary lymphoid tissue). The
lymphocyte recirculation directs naive lymphocytes into the
Peyer's patches in a multistep extravasation cascade by
recognizing the endothelial lining of high endothelial venules
(HEVs, specialized postcapillary venules). When a lymphocyte
finds its cognate antigen, processed by professional antigen-
presenting cells, the cell becomes activatedwithin the germinal
centres (B cell) or outside the centres (T cell) in mesenteric
lymph nodes, starts to proliferate and differentiate and return
to the systemic circulation via the efferent lymphatic system.
Following imprinting, the activated mucosal immunoblast goes
back to the lamina propria of the gut, where it exerts its
effector functions.56,57 In inflammation, changes occur in the
mucosal vasculature, including vasodilatation, hyperaemia and
increased permeability of the vessel wall, which are induced by
the release and actions of various inflammatory mediators,
resulting in enhanced extravasation of leukocytes.58–61 Fur-
thermore, the migration pathways of lymphocytes are altered
by aberrant expression patterns of adhesion molecules and
chemokines, and these may provide an explanation for the
pathogenesis of some extraintestinal manifestations in IBD.56,57
5.1.1. Do intestinal lymphocytes traffic to the joints?
In vitro binding assays revealed that activated human
intestinal immunoblasts adhere efficiently both to intestinal
mucosa and synovial HEVs, but do not bind to peripheral lymph
node vasculature, suggesting that intestinal lymphocytes have
the capacity to enter the joints.62 May et al.63 provided the
first experimental support for the hypothesis that intestinal T
cells activated by antigen migrate to the joints and induce
synovial inflammation, known as the “gut iteropathy con-
cept”. They identified two CD 8+ T cell clones with similar
expression patterns of cytokines, which did not correspond to
classical Th1/Th2 cytokine patterns (interferon-gamma, in-
terleukin (IL)-4, tumour necrosis factor-α and IL-10 produc-
tion). The T cell clones showed an identical tissue distribution,
and were present in the intestinal mucosa, the synovium and
the peripheral blood in a patient with enterogenic SpA.
Less is known about the endothelial adhesion molecules in
synovial membrane that direct homing of activated, gut-
derived leukocytes to joints. Naive lymphocytes leave the
blood via a multistep cascade, consisting of rolling, activation,
firm adhesion and transmigration using several adhesion
molecules and chemotactic signals. Lymphocytes adhere to
mucosal HEVs by using the mucosal homing receptor integrin
α4β7 and its endothelial ligandmucosal addressin cell adhesion
molecule-1 (MAdCAM-1) which is expressed on HEVs in Peyer's
patches and flat-walled venules in lamina propria. MAdCAM-1
belongs to the immunoglobulin superfamily. Human mucosal
lymphocytes do not use α4β7 to adhere to HEVs of inflamed
synovium,62 and therefore, Salmi et al.64 determined whichendothelial adhesion molecules in inflamed synovium support
the binding of mucosa-derived leukocytes. They immunohisto-
chemically stained synovectomy specimens from 20 patients
with chronic arthritis and found that intercellular adhesion
molecule-1 (ICAM-1/CD54) and vascular adhesion protein-1
(VAP-1) are most prominently expressed in synovial vessels,
whereas inflamed synovial vasculature completely lack MAd-
CAM-1. Furthermore, VAP-1 was a dominant endothelial ligand
in supporting the adherence of small lymphocytes (naive cells
and memory cells) and, in particular, large immunoblasts of
gut. In contrast, mucosa-derived macrophages display a
completely different pattern of recognition of vessels in
inflamed synovium using endothelial P-selectin. So, only
blocking the P-selectin interaction is not enough to block the
inhibition of small lymphocytes and immunoblasts trafficking
to inflamed synovial HEVs.64 In 2001, the same group65
determined that gut-derived mucosal leukocytes from IBD
patients arecapable of binding to vessels in inflamed synovium.
They also found that small intestinal lymphocytes use multiple
adhesion molecules and their corresponding endothelial
ligands (CD18-ICAM-1, α4β7a4b1-integrin-VCAM-1, L-selectin-
peripheral lymph node addressins, and CD44) to adhere to
synovial vessels. Binding of activated immunoblasts and
macrophages in IBD patients mostly relies on VAP-1 and P-
selectin and its ligandP-selectin glycoprotein ligand-1 (PSGL-1)
interactions. This is in concert with the results of their previous
study published in 1997 in which they included normal gut.
Furthermore, blocking of VAP-1 inhibited binding of all
leukocytes to joint vessels.65
In conclusion, activated intestinal lymphocytes in IBD
patients adhere to inflamed synovial vessels using multiple
adhesion molecules and their counter receptors, of which
VAP-1 supports the binding of all leukocytes. These findings
provide an explanation for the pathogenesis of joint
inflammation in IBD patients.
5.2. NOD2
Theprevalence ofmutations in theNOD2 gene (R702W,G908R,
and 1007 fs) in CD patients is about 20–30% in the Western
world.66 The risk of developing CD is 20–40 times higher in
individuals that are homozygotic or compound heterozygotic
for mutations in NOD2, whereas this risk is approximately four
times higher in individuals that are heterozygous.66–69 The
NOD2 gene plays a role in the innate immune response by
activating nuclear factor-kB. Nuclear factor-kB is a key
transcriptional regulator controlling the expression of a large
number and variety of genes encoding proinflammatory
cytokines, adhesion molecules, chemokines, growth factors,
and inducible enzymes.70 Mutant NOD2 results in a disturbed
cellular response to bacterial components likemuropeptide N-
acetylmuramic-L-Ala-D-isoGln and lipopolysaccharides, lead-
ing to intracellular persistence of pathogens.71,72 So far, the
exact mechanism in the link between NOD2 mutations and CD
development is still unknown.
5.2.1. AreNOD2carriers at risk for developing arthropathy?
Some studies have been carried out to search for an
association between NOD2 polymorphisms and joint mani-
festations in CDpatients. Peeters et al.73 included 102 patients
with CD and identified an association between NOD2 and
isolated sacroiliitis. Seventy eight percent of CD patients with
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without sacroiliitis (p=0.01). However, this association could
not be confirmed in a recent larger, multicenter cohort of the
same group.21 Several studies found that the NOD2 variants are
not involved in the susceptibility to AS.74–78 On the other hand,
Laukens et al.79 studied 104 patients with SpA and identified a
high prevalence of NOD2 polymorphisms almost similar to the
CD population (49%, in their study) in a subgroup of SpA
patientswith chronic inflammatory gut lesions (38%) compared
to SpA patients with acute inflammation and without gut
involvement as well as a health control group. A significantly
higher frequency of NOD2 mutation carriers was seen in the
subpopulation of SpA patients with chronic inflammatory gut
lesions than in the control population or the other SpA
patients.79 Thus, NOD2 may play a role in the genetic link
between intestinal and joint inflammation.
5.3. HLA-B27 and gut inflammation
Histological studies have demonstrated that SpA patients
may have subclinical intestinal inflammation in the absence
of gastrointestinal symptoms. The inflammatory changes are
divided into an acute type resembling infectious enteroco-
litis and a chronic inflammation that can evolve to clinically
overt CD.80,81 Although the exact mechanisms linking the gut
and joints in SpA patients are unknown, several hypothesis
and animal models for a linkage between gut and joint
inflammation in SpA were described.
The animal model of the HLA-B27/human β2-microglobu-
lin transgenic rats showed that these rats developed
spontaneously inflammatory intestinal and joint disease.
Hammer et al.82 observed a chronic inflammation involving
the stomach and colon in which the colon was most affected
and an axial and peripheral arthritis resembling human SpA.
Inflammation of gut and/or joint did not occur in germ-free
B27 transgenic rats (rats kept in germfree conditions) but
recurred after reintroduction of normal intestinal bacteria.
These findings were most convincing evidence for the
important role of intestinal bacterial flora in the pathogen-
esis of B27-associated gut and joint inflammation.83
A strong association is observed between HLA-B27 and AS
patients in whom more than 90% of patients are HLA-B27
positive.84 Furthermore, 25–78% of IBD patients with AS are
HLA-B27 positive.16,31–33 In contrast, isolated sacroiliitis in CD
is unrelated to HLA-B27.22,31,33 Several theories of how HLA-
B27 may cause IBD include persistence of bacteria because of
altered or defective intracellular killing by HLA-B27 positive
cells and misfolding of the HLA-B27 beta-pocket. Another
hypothesis proposes that HLA-B27 restricted T lymphocytes
can present either bacterial peptides or arthritogenic self-
peptides, thus cross reacting with bacterial antigens.85–87
5.4. The role of other proteins
Macrophages expressing the transmembrane protein CD163,
which is a member of the scavenger receptor cysteine-rich
superfamily that functions in the development and regula-
tion of the immune system, are increased in noninflamed SpA
colonic mucosa and in SpA synovium.88 Demetter et al.89
found that CD163+ macrophages are increased both in CD and
SpA gut mucosa. These observations illustrate that not onlyT cells but also antigen presenting cells accounts for the
relationship between joint and gut inflammation.
Demetter et al.90 observed an upregulation of E-cadherin, a
transmembrane glycoprotein which mediates intercellular
adhesion of epithelial cells, and an upregulation of its
associated catenins in gut mucosa in IBD. This upregulation
was detectable in acute as well as in chronic subclinical gut
inflammation in SpA.89,90 E-cadherin is also a ligand for the
αEβ7 integrin, which is upregulated in colonic mucosa in CD
and AS patients and in inflamed synovial tissue in SpA
patients.91,92 These findings may suggest that these upregula-
tionsmay play a role in the pathogenesis of IBD or SpA, or both.
Statements
- Activated intestinal lymphocytes in IBD patients adhere
to inflamed synovial vessels were VAP-1 supports the
binding of all leukocytes.
- NOD2 does not have a clear association with arthrop-
athy in IBD patients.
- HLA-B27 carriers and AS in IBD patients are associated.6. Treatment
6.1. Peripheral arthropathies
Few studies have been published on the treatment options of
arthropathies in IBD patients.
Type 1 peripheral arthritis mostly occurs during exacer-
bations of IBD activity and therefore, treatment of active
intestinal disease should be the main focus. Type 2 arthritis
follow a course independent of the activity of IBD and the
treatment options are derived from the therapy of axial
arthritis and includes non-steroidal anti-inflammatory drugs
(NSAIDs) or selective cyclooxygenase (COX)-2 inhibitors and
analgesics, physiotherapy and local steroid injection into the
worst-affected joints may be considered. Some studies
suggest an association between NSAIDs and exacerbations of
IBD but data have been conflicting and NSAIDs have been used
by many gastroenterologists to good effect with limited risk
of exacerbating CD or UC. So, no clear evidence exists in an
association between NSAIDs and IBD exacerbations.18,93–95 To
clear this topic further study should be needed.
Sandborn et al.96 performed a placebo controlled pilot trial
to evaluate the safety of the COX-2 inhibitor celecoxib in UC
patients and concluded that short-term treatment with
celecoxib was not associated with a greater clinical and
endoscopic relapse rate than placebo. Some small studies
showed that COX-2 inhibitors in the treatment of peripheral
arthritis and arthralgia in IBD patients was safe and had a
beneficial effect.97–99
6.2. Axial arthropathies
NSAIDs are the first line drug treatment for AS patients and
effective in relief of spinal andperipheral pain and improvement
of spinal mobility.100 In IBD patients with AS a selective COX-2
inhibitor could be used. According to the ‘ASAS/EULAR
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there is no evidence for the efficacy of disease modifying
antirheumatic drugs (DMARDs), including sulfasalazine and
methotrexate, for the treatment of axial disease in AS patients.
In contrast, sulfasalazinemay be considered for AS patientswith
peripheral arthritis.100 Anti-tumour necrosis factor (TNF) alpha
therapy may be appropriate in selected cases (see below).
6.3. Arthropathies and anti-TNF-α therapy
The TNF-α inhibitors infliximab, etanercept and adalimumab
are effective for spinal pain, improvement of spinal function,
as well as peripheral joint pain and swelling in SpA patients.
The ASAS/EULAR group recommended that anti-TNF-α treat-
ment should be given to AS patients with axial and peripheral
symptoms (arthritis and enthesitis) with persistently high
disease activity despite conventional treatment.100 The effect
of infliximab on mucosal inflammation in CD and UC has been
well established and infliximab has been shown to be
efficacious in the treatment of both axial and peripheral
arthropathy in SpA.101–105 The results of studies published
about the treatment of arthropathy in IBD patients with
infliximab are encouraging. These studies showed clinical
improvement in the severity of pain, duration of morning
stiffness, and tender joint count in peripheral arthritis,
enthesitis, arthralgia, isolated sacroiliitis and/or AS in active
and inactive CD. Infliximab also improved gastrointestinal
symptoms and was well tolerated.106–111 The results of these
studies suggest a possible role of infliximab in the treatment of
peripheral as well as axial arthropathy in IBD patients.
Etanercept is well tolerated and efficacious in the
treatment of joint manifestations in SpA112,113 and CD patients
but not in the treatment of CD colitis.114 Marzo et al.115
reported an improvement in articular symptoms, but the CD
colitis persisted or flared in two patients.
Adalimumab is effective in reducing joint symptoms in AS
patients resulting in an improvement of the physical function
and quality of life.116–118 In CD patients adalimumab is also
effective and well tolerated but no studies have been
published about the effectiveness of adalimumab on ar-
thropathies in IBD patients.119
Statements
- Treatment of active intestinal disease should be the
main focus.
- COX-2 inhibitors should be given to reduce pain of
peripheral arthritis, arthralgia and axial arthritis in
IBD patients.
- Anti-TNF-α therapy may be considered to CD patients
with persistently high articular activity (axial and/or
peripheral).7. Conclusion
Arthropathies in IBD are clinically divided into peripheral and
axial involvement and may be classified as one of the SpA.
Peripheral arthropathy and IBP can be diagnosed clinically,
but diagnosis of isolated sacroiliitis is based on imagingtechniques and diagnosis of AS is based on the combination of
clinical features and imaging. Unfortunately, there is no
reliable laboratory test that can be used as a diagnostic tool in
the management or diagnosis of these arthropathies. Joint
symptoms in IBD represent a major medical problem in these
patients with a worse health related quality of life compared
with IBD patients without joint symptoms. Treatment of
active intestinal disease should be the main focus for
peripheral arthritis type 1 and standard treatment for
peripheral arthropathy unrelated to exacerbations of the
bowel activity and axial arthropathy includes NSAIDs/COX-2
inhibitors. Anti-TNF-α treatment may be given to patients
with persistently high disease activity despite conventional
treatments. A close relationship between joint and gut
inflammation has been confirmed by several studies but the
exact mechanism of the link between arthropathies and IBD is
still unknown. Immunologic and genetic factors are thought
to play a role. Future studies are needed to understand the
pathogenesis of joint manifestations in IBD patients.Acknowledgements
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